A Phase 1/2a Study of REGN7041 (anti-CD3 monoclonal antibody) in patients with Active Noninfectious Uveitis affecting the Posterior Segment

Status

Not yet recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521713-57-00

Enrollment

Registered

2026-03-05

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Noninfectious Uveitis

Brief summary

Occurrence of Treatment-Emergent Adverse Events (TEAEs)

Detailed description

Concentrations of REGN7041 in serum, Incidence of Anti-Drug Antibodies (ADAs) to REGN7041 in serum, Magnitude of ADAs to REGN7041 in serum

Interventions

DRUGREGN7041

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Occurrence of Treatment-Emergent Adverse Events (TEAEs)	—

Secondary

Measure	Time frame
Concentrations of REGN7041 in serum, Incidence of Anti-Drug Antibodies (ADAs) to REGN7041 in serum, Magnitude of ADAs to REGN7041 in serum	—

Outcome results

None listed

Source: EU CTIS · Data processed: Mar 6, 2026